Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iclaprim - Motif Bio

Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 15 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia
  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • No development reported Nosocomial infections
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 14 Feb 2019 Motif Bio plans to meet US FDA to discuss complete response letter for iclaprim to address the deficiencies
  • 14 Feb 2019 Motif Bio receives complete response letter from the FDA for iclaprim in Skin-and-soft tissue-infections
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Nosocomial-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top